Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

Altimmune ALT has entered a more capital-intensive stage with pemvidutide advancing across metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). Its larger cash position gives the company more room to execute.

The investment case remains balanced. Pemvidutide offers several clinical paths to value creation, but Altimmune still depends on one experimental drug, faces a long pivotal timeline and may need more capital for additional late-stage development.

Altimmune's Cash Runway Supports the Core Program

Altimmune ended June 2026 with $519 million in cash, cash equivalents and short-term investments, up from $332 million at the end of March. Management expects the balance to fund operations into 2029.

That runway is expected to cover the phase III MASH program through its 52-week readout and the ongoing phase II ALD study. Altimmune has also secured manufacturing capacity for the global MASH study, reducing one execution variable as development scales.

Altimmune, Inc. Price and Consensus

Altimmune, Inc. price-consensus-chart | Altimmune, Inc. Quote

ALT's Pipeline Upside Still Centers on One Drug

Pemvidutide is a balanced 1:1 glucagon/GLP-1 dual receptor agonist being developed for MASH, AUD and ALD. Phase IIb MASH data showed MASH resolution without worsening fibrosis at 24 weeks, sustained through 48 weeks.

The AUD phase II study also met its primary endpoint, cutting heavy drinking days by 1.45 days per week versus placebo at week 24, while phase II ALD data are expected in the second half of 2027. Still, all three opportunities depend on the same molecule.

Altimmune's Valuation Reflects Both Hope and Risk

ALT trades at a trailing 12-month price-to-book ratio of 1.16, below its five-year median of 2.39 and within a historical range of 0.78 to 5.85. The current multiple therefore remains below the level that has been typical over the past five years.

The valuation also reflects a business without marketed products. Fiscal 2025 revenues were only $41,000, leaving Altimmune's equity value tied primarily to pemvidutide's clinical and regulatory success rather than an established commercial base.

ALT Faces a Long Phase III Timeline and Funding Gap

The phase III PERFORMA study in MASH is expected to deliver 52-week data in 2029. Enrollment is projected to take 18 to 24 months, creating a lengthy period in which trial recruitment and execution must stay on schedule.

The current cash plan excludes a potential phase III AUD program. Advancing that indication would therefore require additional financing, and although management prefers non-dilutive sources, new equity funding could expose shareholders to dilution.

Altimmune's Competition Limits Room for Error

MASH is already a demanding competitive market. Novo Nordisk NVO has FDA approval for Wegovy in adults with MASH and moderate-to-advanced fibrosis. Madrigal Pharmaceuticals MDGL markets Rezdiffra for adults with noncirrhotic MASH and moderate-to-advanced fibrosis.

Altimmune also faces other GLP-1 combinations, FGF21 therapies and thyroid hormone receptor-beta approaches in development. In AUD, approved drugs such as naltrexone and acamprosate add another hurdle, making differentiation in efficacy, tolerability and execution important.

ALT's Mixed Style Scores Favor a Cautious Stance

Altimmune's stronger balance sheet and broader pemvidutide program support continued clinical progress, but the stock still carries substantial concentration, timeline and financing risk. That mix argues for patience rather than treating the improved cash position as a stand-alone buy signal.

ALT currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

Its Momentum Score of A points to favorable momentum characteristics, but its Value Score of F, Growth Score of F and VGM Score of F weaken the case for investors seeking stronger value, growth or all-around style characteristics. A #3 rank fits a hold posture rather than a clear buy signal.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research